Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 23, 2019

CHMP adopts positive opinion for BAVENCIO plus Axitinib for advanced renal cell carcinoma

EMD Serono, the biopharmaceutical business of Merck, and Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of BAVENCIO (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

CHMP adopts positive opinion for BAVENCIO plus Axitinib for advanced renal cell carcinoma